Avidity Biosciences, Inc. Common Stock (RNAM) Stock Price
RNAMStock
$0.00
Market Cap—
P/E—
PEG Ratio—
Div yield—
Beta—
RNAM Share Price Chart
Favorite Metrics
VGM Score85.84
RNAM Analyst Recommendations
Nov 2025
Dec 2025
Jan 2026
Feb 2026
3.76
3.50
3.50
3.50
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RNAMAvidity Biosciences, Inc. Common Stock | — | A | — | $0.00 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Avidity Biosciences, Inc. Common Stock
Avidity Biosciences is a biopharmaceutical company developing a novel class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs). The company has three programs in registrational clinical trials: Del-desiran for myotonic dystrophy type 1, Del-zota for Duchenne muscular dystrophy, and Del-brax for facioscapulohumeral muscular dystrophy.